Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Novartis: Buy This Dividend Aristocrat For Consistent Income
07:17am, Tuesday, 26'th Sep 2023
Novartis' core EPS payout ratio is poised to come in at around 51% in 2023. The Swiss drugmaker grew at a solid clip in the first half of this year. The company enjoys an AA- credit rating from rating
Novartis (NVS) Lutathera Meets Primary Goal in Phase III Study
01:32pm, Monday, 25'th Sep 2023
Novartis' (NVS) radioligand therapy Lutathera reports statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors
Morgan Stanley sees biopharma sector as a 'safe haven'
10:01am, Monday, 25'th Sep 2023
Morgan Stanley (NYSE:MS) expects the EU biopharma sector to offer a safe haven from weakening growth/higher real yields. “Whilst we continue to favour growth/innovation narratives in biopharma over
Are Gene Therapy Stocks The Market's Next Big Winners?
08:06am, Monday, 25'th Sep 2023
It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmaceutical NASDAQ: BMRN and Sarepta Therapeutics NASD
Novartis confirms Sandoz spin-off for October 4, 2023
01:22am, Monday, 25'th Sep 2023
Novartis on Monday confirmed its plans for a 100% spin-off of the Sandoz business on Oct. 4 after shareholders gave their approval earlier this month.
Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement
10:33pm, Sunday, 24'th Sep 2023
Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. Once again, a big phar
BeiGene regains rights for cancer drug after Novartis deal termination
06:14am, Tuesday, 19'th Sep 2023
BeiGene said on Tuesday it would regain rights to develop and manufacture its cancer drug after a deal termination with Novartis.
Novartis' (NVS) Shareholders Approve Sandoz Separation
01:33pm, Monday, 18'th Sep 2023
Novartis' (NVS) shareholders vote in favor of the 100% spin-off of Sandoz into a new publicly traded standalone company.
Novartis shareholders vote in favour of Sandoz spin-off
05:34am, Friday, 15'th Sep 2023
Novartis shareholders on Friday voted in favour of spinning off the Swiss company's generic-drugs business Sandoz, with investors holding 99.7% of the represented capital supporting the proposal.
2 Dividend Stocks to Buy and Hold Forever
10:00am, Wednesday, 13'th Sep 2023
Novartis and Microsoft are both leaders and innovators in their respective industries. Novartis is giving its business a makeover in a way that could boost long-term growth.
Novartis' (NVS) Sandoz Gets Rights for Stelara Biosimilar
01:35pm, Tuesday, 12'th Sep 2023
Novartis (NVS) announces an agreement with Samsung Bioepis for exclusive rights to commercialize the biosimilar of Stelara in Europe and North America. The company discontinues the development of GT00
NVS vs. LLY: Which Stock Is the Better Value Option?
12:50pm, Tuesday, 12'th Sep 2023
Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Novartis (NVS) and Eli Lilly (LLY). But which of these two stocks presents investors with the better value opportunity
UK's Syncona writes off 54.5 mln stg after Novartis ends Gyroscope's therapy
02:44am, Monday, 11'th Sep 2023
British healthcare investment firm Syncona said on Monday Novartis has stopped the development of experimental eye treatment, GT005, which would result in payments write-off of 54.5 million pounds ($6
Here's Why Novartis (NVS) is a Strong Value Stock
11:18am, Wednesday, 06'th Sep 2023
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Novartis names new board member after international boss steps down
01:40am, Wednesday, 06'th Sep 2023
Novartis has appointed AbbVie executive Patrick Horber to its executive committee, the Swiss pharmaceuticals maker said on Wednesday, after Chief Commercial Officer Marie-France Tschudin stepped down.
